Skip to main content
. 2021 Jan 15;11:1567. doi: 10.1038/s41598-021-81038-5

Table 1.

Patients’ characteristics.

CTRL (n = 24) CAD (n = 19) p values
Age (years) 57.0 ± 7.3 59.2 ± 8.8 0.364
Sex, male (%) 8 (32.0) 12 (68.0) 0.054
BMI (kg/m2) 23.7 ± 3.2 24.8 ± 2.4 0.241
AC (cm) 85.7 ± 10.2 89.2 ± 6.8 0.278
SBP (mmHg) 117.4 ± 12.1 124.8 ± 15.6 0.086
DBP (mmHg) 73.1 ± 12.9 71.9 ± 6.8 0.709
CAD
 1-vessel disease 0 (0.0) 2 (10.5)
 2-vessel disease 0 (0.0) 5 (26.3)
 3-vessel disease 0 (0.0) 12 (63.2)
Complications
 Diabetes mellitus (%) 0 (0.0) 0 (0.0) 1.000
 Hypertension (%) 5 (20.8) 10 (52.6) 0.032
 Hyperlipidemia (%) 3 (12.5) 8 (42.1) 0.029
Laboratory measurements
 WBC (× 109/L) 6.3 ± 2.3 6.2 ± 1.6 0.953
 HbA1c (%) 2.7 ± 1.3 3.5 ± 2.3 0.448
 TG (mmol/L) 1.4 ± 1.1 2.0 ± 1.2 0.085
 LDL-c (mmol/L) 2.7 ± 0.6 2.7 ± 1.1 0.984
 HDL-c (mmol/L) 1.1 ± 0.3 0.9 ± 0.2 0.070
Left heart function
 EF (%) 55.2 ± 8.8 57.1 ± 11.4 0.544
Medication
 β-blocker 10 (41.7) 17 (89.5) 0.001
 ACEI/ARB 8 (33.3) 9 (47.4) 0.356
 Statin 2 (8.3) 12 (63.2) 0.000

Data are presented as mean ± SD or the number (%) of patients.

BMI Body Mass Index, AC abdominal circumference, SBP systolic blood pressure, DBP diastolic blood pressure, WBC white blood cell, HbA1c glycated hemoglobin, TGs triglycerides, LDL-c low-density lipoprotein cholesterol, HDL-c high-density lipoprotein cholesterol, EF ejection fraction, ACEI angiotensin-converting enzyme inhibitors, ARB angiotensin receptor blockers.